莱美药业
(300006)
| 流通市值：49.10亿 | | | 总市值：49.10亿 |
| 流通股本：10.56亿 | | | 总股本：10.56亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 377,193,804.76 | 198,396,229.11 | 795,597,751.21 | 605,644,339.58 |
| 营业收入 | 377,193,804.76 | 198,396,229.11 | 795,597,751.21 | 605,644,339.58 |
| 二、营业总成本 | 404,266,945.2 | 207,297,310.76 | 883,123,222.76 | 659,835,849.32 |
| 营业成本 | 167,362,192.2 | 85,670,209.93 | 283,326,914.55 | 221,662,241.7 |
| 税金及附加 | 6,675,586.99 | 3,457,359 | 17,995,039.77 | 14,105,878.02 |
| 销售费用 | 149,786,920.53 | 74,837,282.59 | 396,723,869.68 | 299,437,003.09 |
| 管理费用 | 63,800,620.81 | 32,463,562.07 | 139,206,935.58 | 94,248,180.74 |
| 研发费用 | 22,314,499.67 | 13,768,411.89 | 64,732,407.62 | 44,369,887.69 |
| 财务费用 | -5,672,875 | -2,899,514.72 | -18,861,944.44 | -13,987,341.92 |
| 其中:利息费用 | 6,648,620.04 | 3,586,482.36 | 11,130,990.33 | 7,892,894.42 |
| 其中:利息收入 | 12,602,443.54 | 6,570,079.19 | 29,653,509.12 | 22,589,630.94 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -15,530,666.39 | -9,036,151.47 | -18,877,654.65 | -17,722,492.92 |
| 资产处置收益 | 27,298.59 | 25,052.59 | 494,537.15 | 65,503.69 |
| 资产减值损失(新) | -1,752,750.17 | 69,648.58 | -34,345,663.15 | -2,904,015.43 |
| 信用减值损失(新) | -2,555,822.8 | -1,812,801.83 | -11,281,733.7 | -5,408,968.14 |
| 其他收益 | 17,977,040.8 | 4,408,944.53 | 45,714,195.51 | 39,354,646.69 |
| 四、营业利润 | -28,908,040.41 | -15,246,389.25 | -105,821,790.39 | -40,806,835.85 |
| 加:营业外收入 | 82,139.76 | 69,623.99 | 30,992,694.71 | 30,360,820.78 |
| 减:营业外支出 | 171,555.28 | 65,029.16 | 709,067.89 | 252,244.87 |
| 五、利润总额 | -28,997,455.93 | -15,241,794.42 | -75,538,163.57 | -10,698,259.94 |
| 减:所得税费用 | -99,808.41 | -1,282,177.58 | 4,550,293.14 | 4,824,830.06 |
| 六、净利润 | -28,897,647.52 | -13,959,616.84 | -80,088,456.71 | -15,523,090 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -28,897,647.52 | -13,959,616.84 | -80,088,456.71 | -15,508,670.55 |
| 终止经营净利润 | - | - | - | -14,419.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -31,377,308.78 | -13,775,322.52 | -87,804,417.25 | -26,416,692.1 |
| 少数股东损益 | 2,479,661.26 | -184,294.32 | 7,715,960.54 | 10,893,602.1 |
| 扣除非经常损益后的净利润 | -32,233,216.04 | -14,291,100.05 | -118,869,702.88 | -55,643,185.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.01 | -0.08 | -0.03 |
| (二)稀释每股收益 | -0.03 | -0.01 | -0.08 | -0.03 |
| 八、其他综合收益 | - | - | -118,753,814.95 | - |
| 归属于母公司股东的其他综合收益 | - | - | -118,753,814.95 | - |
| 九、综合收益总额 | -28,897,647.52 | -13,959,616.84 | -198,842,271.66 | -15,523,090 |
| 归属于母公司股东的综合收益总额 | -31,377,308.78 | -13,775,322.52 | -206,558,232.2 | -26,416,692.1 |
| 归属于少数股东的综合收益总额 | 2,479,661.26 | -184,294.32 | 7,715,960.54 | 10,893,602.1 |
| 公告日期 | 2025-08-22 | 2025-04-24 | 2025-03-22 | 2024-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |